Compare XYF & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XYF | NYXH |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 190.6M |
| IPO Year | 2018 | 2021 |
| Metric | XYF | NYXH |
|---|---|---|
| Price | $3.45 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 116.5K | 64.0K |
| Earning Date | 03-25-2026 | 03-19-2026 |
| Dividend Yield | ★ 12.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $204.26 |
| Revenue Next Year | N/A | $136.06 |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $3.02 |
| 52 Week High | $20.36 | $8.64 |
| Indicator | XYF | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 30.97 |
| Support Level | N/A | N/A |
| Resistance Level | $5.07 | $4.99 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 1.80 | 11.67 |
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.